When was Bioligo Biotechnology founded?

Bioligo Biotechnology was founded in 2011 and raised its 1st funding round 10 years after it was founded.

Where is Bioligo Biotechnology located?

Bioligo Biotechnology is headquartered in Shanghai, China.

Is Bioligo Biotechnology a funded company?

Bioligo Biotechnology is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Oct 25, 2021.

When was the latest funding round of Bioligo Biotechnology?

Bioligo Biotechnology's latest funding was a $***** Series A round on Oct 25, 2021, with participation from 1 investor. Its primary sector is Services for Healthcare Providers. In China, the Services for Healthcare Providers sector has seen $72.5M in funding in 2026 to date.

Where does Bioligo Biotechnology rank among its competitors?

Bioligo Biotechnology ranks 28th amongst 46 active competitors, of which 6 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sequome, which secured $10.6M in Jun, 2025.

Who are the top competitors of Bioligo Biotechnology?

Bioligo Biotechnology's top competitors include Catalys Pacific, Orphalan and NIMBLE Diagnostics. Among them, Sequome secured the most recent funding round in June, 2025.

Bioligo Biotechnology - 2026 Company Profile, Funding & Competitors

Company Details

Website: en.bioligo.com/
Email ID: *****@bioligo.cn
Phone Number: +86 **********

Key Metrics

Founded Year

2011

Location

Shanghai, China

Stage

Series A

Latest Funding Round

Series A, Oct 25, 2021, $*****

Investors

The Carlyle Group & 1 more

Ranked

28^th among 46 active competitors

Similar Companies

Catalys Pacific & 45 more

View Bioligo Biotechnology's full profile

Bioligo Biotechnology has raised funding over 1 round. Its latest funding round was a Series A round on Oct 25, 2021 for $*****. 1 investor participated in its latest round. Bioligo Biotechnology has 2 institutional investors.

Here is the list of recent funding rounds of Bioligo Biotechnology:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 25, 2021	1509445	Series A	9269011	2018836	4489758	5503415

Access funding benchmarks and valuations. Sign up today!

View details of Bioligo Biotechnology's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Bioligo Biotechnology include Catalys Pacific, Orphalan and NIMBLE Diagnostics. Here is the list of Top 10 competitors of Bioligo Biotechnology, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Catalys Pacific 2019, Cayman Islands, Unfunded	Provider of diagnostic healthcare investment services	-	-	42/100
2nd	Orphalan 2011, Paris (France), Funding Raised	Developer and provider of access to innovative treatments to patients with rare diseases	-	Kreos Capital, Advent Life Sciences & 1 others	41/100
3rd	NIMBLE Diagnostics 2022, Badalona (Spain), Seed	Developer of diagnostic device for the detection of cardiovascular conditions	$1.08M	Grow Venture Partners, Ship2B & 4 others	35/100
4th	Monarch Diagnostics 2019, Irvine (United States), Unfunded	Provider of diagnostic testing services	-	-	35/100
5th	Shine Spect Janesville (United States), Unfunded	Provider of diagnostic radiopharmaceutical products and artificial intelligence solutions	-	-	34/100
6th	Droplet 2015, Gurugram (India), Acquired	Provider of home pathology sample collection and diagnostic tests services	$227K	Tata 1mg	32/100
7th	Amber Pharmacy 2008, Singapore (Singapore), Acquired	Provider of customized approach to diagnosing and delivering specialty medications, with a patient-centric focus on convenient access, personalized care, and comprehensive support	-	-	31/100
8th	Sequome 2022, United States, Series B	Provider of decodes and designs sequences to develop sequence medicines	$10.6M	-	31/100
9th	Nutrasource 2002, Guelph (Canada), Acquired	Provider of marketing services for healthcare, nutraceutical & pharmaceutical sector	-	Maxim Corporate Partners	31/100
10th	PharmaReview 2011, London (United Kingdom), Late Stage	Provider of review pharmaceutical services for the lifesceince industry	-	Bridgepoint Group, HHS	30/100
28th	Bioligo Biotechnology 2011, Shanghai (China), Series A	Provider of raw materials and technical services for diagnostic industry	-	The Carlyle Group, CEC Capital	21/100